Combined organization brings broader predictive capabilities to drug discovery at scale RADNOR, Pa., July 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced it has signed a definitive agreement to acquire Chemaxon, a leading provider of cheminformatics software. The transaction is expected to close in the second half of 2024, subject to regulatory approval and other customary closing conditions. In 2024, Chemaxon is expected to gene ...

Certara, excluding Chemaxon, is reiterating 2024 revenue, adjusted EBITDA margin, and adjusted diluted earnings per share guidance consistent with the May 7th earnings call. Following transaction close, Certara will update its 2024 guidance to include contribution from Chemaxon and expects to maintain its 2024 adjusted EBITDA margin guidance of 31-33%. Media Contact: Reiterates full year 2024 guidance Forward-Looking Statements Chemaxon develops leading software products for chemical structure drawing, prop ...

Core Insights - Certara, Inc. is set to release its financial results for Q2 2024 on August 6, 2024, after market close, followed by a conference call at 5:00 PM ET to discuss the results [4]. Company Overview - Certara is a global leader in model-informed drug development, utilizing biosimulation software, technology, and services to enhance traditional drug discovery and development processes [3]. - The company serves over 2,400 clients, including biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries [3].

RADNOR, Pa., July 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2024 after the market close on Tuesday, August 6th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A liv ...

RADNOR, Pa., June 17, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today unveiled its next-generation CoAuthor regulatory writing software. CoAuthor is an advanced writing platform designed for medical writers. It combines generative AI, document templates, Microsoft Word integration, and structured content authoring tools. CoAuthor accelerates the creation of regulatory documents while maintaining a "human in the loop" approach to the use of gen ...

RADNOR, Pa., June 17, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today unveiled its next-generation CoAuthor regulatory writing software. CoAuthor is an advanced writing platform designed for medical writers. It combines generative AI, document templates, Microsoft Word integration, and structured content authoring tools. CoAuthor accelerates the creation of regulatory documents while maintaining a "human in the loop" approach to the use of gen ...

About Certara Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include nearly 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at www.certara.com. RADNOR, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Jefferies ...

RADNOR, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has appointed Rona Anhalt as Chief Human Resources Officer and Daniel Corcoran as General Counsel. "Rona and Daniel are leaders in their fields. They have proven track records of growing teams and building high-performing businesses," said William F. Feehery Ph.D., CEO, Certara. "I'm confident they will further Certara's mission of accelerating medicines to patients through the del ...

Certara, Inc. (NASDAQ:CERT) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants David Deuchler - Investor Relations William Feehery - Chief Executive Officer John Gallagher - Chief Financial Officer Conference Call Participants David Windley - Jefferies Luke Sergott - Barclays Michael Ryskin - Bank of America Max Smock - William Blair Steve Dechert - KeyBanc Operator Good day and thank you for standing by. Welcome to the Certara First Quarter 2024 Earnings Conference Call. [Operator ...

Certara, Inc. (CERT) came out with quarterly earnings of $0.10 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.12 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post earnings of $0.11 per share when it actually produced earnings of $0.09, delivering a surprise of -18.18%.Over the last four quarters, the company has not been able to surpass consensus EPS estimates.Certara, which belongs to t ...